Dual-Site Theta Burst Stimulation May Reduce Suicidal Ideation
Four-day treatment targeting the prefrontal cortex and cerebellum produced larger reductions in suicidal ideation scores than prefrontal stimulation alone in adolescents with major depressive disorder.
Clinical Report: Dual-Site Theta Burst Stimulation May Reduce Suicidal Ideation
Overview
A randomized clinical trial found that dual-site accelerated intermittent theta burst stimulation (aiTBS) targeting the left dorsolateral prefrontal cortex and cerebellum significantly reduced suicidal ideation in adolescents with major depressive disorder compared to single-site stimulation. The dual-site group showed greater reductions in Beck Scale for Suicide Ideation scores and higher response and remission rates.
Background
Adolescent suicide is a critical public health issue, particularly influenced by major depressive disorder (MDD). The prevalence of suicidal ideation among adolescents with MDD is notably high, making effective treatment strategies essential. This study explores the efficacy of dual-site aiTBS as a potential intervention for reducing suicidal ideation in this vulnerable population.
Data Highlights
Group
Mean Beck Scale for Suicide Ideation Score (Baseline)
Mean Beck Scale for Suicide Ideation Score (Day 4)
Response Rate
Remission Rate
Dual-Site
22.6
8.2
59%
48%
Single-Site
23.3
13.9
37%
30%
Key Findings
Dual-site aiTBS resulted in a greater reduction in suicidal ideation scores compared to single-site stimulation.
Mean Beck Scale for Suicide Ideation scores decreased significantly in the dual-site group from 22.6 to 8.2.
Response rates were 59% in the dual-site group versus 37% in the single-site group.
Remission rates were 48% in the dual-site group compared to 30% in the single-site group.
Common adverse events included pain at stimulation sites and dizziness, resolving within 30 minutes.
No serious adverse events were reported in either group.
Clinical Implications
The findings suggest that dual-site aiTBS may be a promising intervention for adolescents with major depressive disorder and suicidal ideation. Clinicians should consider the potential benefits of targeting both the dorsolateral prefrontal cortex and cerebellum in treatment protocols.
Conclusion
This study indicates that dual-site aiTBS may effectively reduce suicidal ideation in adolescents with major depressive disorder, warranting further investigation into its clinical application.
